Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF, QuANTUM-First Study Group

Open source

DOI: 10.1016/s0140-6736(23)00464-6
Published: 2023 May 13
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-23-00464-6,
  title = {Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.},
  author = {Erba HP and Montesinos P and Kim HJ and Patkowska E and Vrhovac R and Žák P and Wang PN and Mitov T and Hanyok J and Kamel YM and Rohrbach JEC and Liu L and Benzohra A and Lesegretain A and Cortes J and Perl AE and Sekeres MA and Dombret H and Amadori S and Wang J and Levis MJ and Schlenk RF and QuANTUM-First Study Group},
  year = {2023},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(23)00464-6},
  url = {https://doi.org/10.1016/s0140-6736(23)00464-6}
}

RIS

TY  - JOUR
TI  - Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
AU  - Erba HP
AU  - Montesinos P
AU  - Kim HJ
AU  - Patkowska E
AU  - Vrhovac R
AU  - Žák P
AU  - Wang PN
AU  - Mitov T
AU  - Hanyok J
AU  - Kamel YM
AU  - Rohrbach JEC
AU  - Liu L
AU  - Benzohra A
AU  - Lesegretain A
AU  - Cortes J
AU  - Perl AE
AU  - Sekeres MA
AU  - Dombret H
AU  - Amadori S
AU  - Wang J
AU  - Levis MJ
AU  - Schlenk RF
AU  - QuANTUM-First Study Group
PY  - 2023
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(23)00464-6
UR  - https://doi.org/10.1016/s0140-6736(23)00464-6
ER  -

APA

HP, E., P, M., HJ, K., E, P., R, V., P, Ž., PN, W., T, M., J, H., YM, K., JEC, R., L, L., A, B., A, L., J, C., AE, P., MA, S., H, D., S, A., J, W., MJ, L., RF, S., & Group, Q. S. (2023). Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(23)00464-6

Source records

pubmed · retrieved 2026-09-26T09:43:25.644Z